Research News

---

Topic: Hormonal Therapies (view all topics)

Tags for topic Hormonal Therapies:

• After surgery (also called "adjuvant")
• Arimidex
• Aromasin
• Aromatase Inhibitors
• Before surgery (also called "neoadjuvant")
• Evista
• Fareston
• Faslodex
• Femara
• Not applicable (no surgery)
• Planning Hormonal Therapy
• Prophylactic (to lower risk if you've never been diagnosed with breast cancer)
• Selective Estrogen Receptor Modulators
• Tamoxifen

View articles by month and year

• Tamoxifen and Chemo Reduce Risk of New, Second Cancer

  Published on December 25, 2007 at 12:00 am

  • Tags: Standard, Tamoxifen, and After surgery (also called "adjuvant")

  Tamoxifen and chemotherapy reduce the risk of developing a new, second breast cancer in the other breast.

• Arimidex More Effective Than Tamoxifen for Postmenopausal Women

  Published on December 17, 2007 at 12:00 am

  • Tags: Arimidex, Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  Another year of results from the ATAC trial continues to show that Arimidex has more benefits than tamoxifen for post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.

• Postmenopausal Women Benefit from Longer Hormonal Therapy

  Published on December 11, 2007 at 12:00 am

  • Tags: Arimidex, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.

• Different Hormonal Therapies Cause Different Side Effects

  Published on November 14, 2007 at 12:00 am

  • Tags: Aromasin, Tamoxifen, and After surgery (also called "adjuvant")

  Hormonal therapy medicines used to reduce the risk of recurrence have different side effects.

• Chemotherapy and Aromatase Inhibitors Can Cause Bone Loss

  Published on September 19, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  A new study provides more evidence that bone loss is a significant risk for women who receive chemotherapy and/or an aromatase inhibitor to treat breast cancer.

• Women Stop Taking Hormonal Therapy Too Soon Because of Side Effects

  Published on September 6, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  Side effects cause many women to stop taking hormonal therapy medicine earlier than prescribed a new study reports.

• Hormonal Therapy Medicines Have Improved Survival

  Published on April 23, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), Aromatase Inhibitors, and Planning Hormonal Therapy

  Hormone-receptor-positive breast cancer survival rates have increased faster than survival rates for hormone-receptor-negative breast cancer.

• Tamoxifen Plus Chemo Boosts Survival

  Published on April 3, 2007 at 12:00 am

  • Tags: Tamoxifen, After surgery (also called "adjuvant"), and Planning Hormonal Therapy

  Hormonal therapy and chemotherapy boosts survival for women with early breast cancer.

• Age Affects Treatment Side Effects

  Published on February 20, 2007 at 12:00 am

  • Tags:

  Side effects of breast cancer treatment can vary with age.

• Aromatase Inhibitors Offer Better Survival Than Tamoxifen for Postmenopausal Women

  Published on February 12, 2007 at 12:00 am

  • Tags: Arimidex, Aromasin, Femara, Tamoxifen, After surgery (also called "adjuvant"), and Aromatase Inhibitors

  Switching to an aromatase inhibitor after two to three years of tamoxifen offers improved survival compared to five years of tamoxifen for post-menopausal women with hormone-receptor-positive, early-stage breast cancer.